Delek Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Delek Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$4.92M	–	228
2018 Q2	$4.92M	Buy	+50,000	New	+$4.96M	0.21%	132

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Delek Group's ALNY Position: Q3 2018 in Review

Delek Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2018, closing a stake of 50,000 shares — an estimated $4.92M sold.

Delek Group first reported a position in ALNY in Q2 2018 and held it in 1 quarter. The position peaked at $4.92M in Q2 2018. 305 funds tracked by Wall St. Rank hold ALNY as of Q3 2018.

Delek Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Delek Group sold 50,000 Alnylam Pharmaceuticals shares in Q3 2018, an estimated $4.92M.
Delek Group first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Delek Group's Alnylam Pharmaceuticals position peaked at $4.92M in Q2 2018.
305 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2018.

Based on Delek Group's 13F filing for Q3 2018, filed 14 Nov 2018.